For the quarter ending 2025-09-30, COEPW had $2,911,761 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -2,898,763 | -7,755,527 |
| Depreciation and amortization | 295,303 | 590,606 |
| Right of use asset amortization | 10,462 | 20,218 |
| Amortization of debt discount | 57,994 | 487,641 |
| Stock based compensation | 213,035 | 788,752 |
| Forgiveness of interest | - | -19,447 |
| Shares issued for non-employee services | 315,000 | 2,407,570 |
| Debt converted to equity | - | 168,113 |
| Warrants issued for services | 0 | 824,295 |
| Change in fair value of derivative liability warrants | - | -108,000 |
| Change in fair value of derivative liability | -135,055 | 1,041,484 |
| Change in fair value of derivative liability warrants | -50,250 | 0 |
| Gain on writedown of liability | 159,035 | - |
| Loss on shares issued for conversion of debt | 0 | 0 |
| Loss on writedown of derivative liability | 135,054 | - |
| Unrealized loss on marketable securities | -568,868 | 390,566 |
| Accounts receivable | 52,500 | 30,000 |
| Interest receivable | 3,541 | 0 |
| Prepaid assets | -103,004 | 159,237 |
| Accounts payable | -241,188 | -240,939 |
| Accrued expenses | -89,967 | -320,675 |
| Customer deposit | -169,941 | -218,555 |
| Right of use liability | -10,747 | -20,568 |
| Other current liabilities | -115,000 | - |
| Net cash used in operating activities | -2,152,217 | -4,762,909 |
| Increase in subscription receivable in exchange for cash | 0 | 0 |
| Net cash used in investing activities | 0 | 0 |
| Cash received for stock subscription | - | 0 |
| Proceeds from notes payable | 0 | 990,000 |
| Repayment of notes payable | 0 | -218,750 |
| Shares issued for sepa | 2,039,195 | - |
| Shares issued for cash | 3,024,633 | - |
| Warrants issued for cash | 150 | 500 |
| Preferred stock offering | 0 | 5,455,000 |
| Net cash provided by financing activities | 5,063,978 | 6,226,750 |
| Net increase (decrease) in cash | 2,911,761 | 1,463,841 |
| Cash and cash equivalents at beginning of period | 532,885 | - |
| Cash and cash equivalents at end of period | 4,908,487 | - |
Coeptis Therapeutics Holdings, Inc. (COEPW)
Coeptis Therapeutics Holdings, Inc. (COEPW)